Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 4:28 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 4:28 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Teva Stock Falls as Novartis Brings Another Copaxone Generic
by Zacks Equity Research
Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.
Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints
by Zacks Equity Research
Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.
Teva Completes Sale of Women's Health Segment for $703M
by Zacks Equity Research
Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
by Zacks Equity Research
Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
by Zacks Equity Research
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Parkinson's Disease Space Again Under Spotlight This Week
by Zacks Equity Research
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
by Zacks Equity Research
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
by Zacks Equity Research
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.
New Strong Sell Stocks for December 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Teva's Migraine Candidate Gets Priority Review From FDA
by Zacks Equity Research
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA
Bear of the Day: Mallinckrodt PLC (MNK)
by Kevin Cook
Generic drug makers are one of the worst performing industries this year and there's little sign of a turnaround
Teva's New CEO Re-Shuffles Senior Management, Stock Up 7%
by Zacks Equity Research
Teva (TEVA) announced several organizational changes in order to save costs and improve productivity.
Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
by Zacks Equity Research
Per an Israeli news release, Teva (TEVA) is expected to lay off 4000 employees
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up
by Zacks Equity Research
Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates
by Zacks Equity Research
BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3
by Zacks Equity Research
Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.
Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut
by Zacks Equity Research
Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.
Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
by Zacks Equity Research
Momenta Pharmaceuticals (MNTA) study to evaluate a biosimilar version of Orencia failed which overshadowed the third-quarter results.